Phase II Study of Calcitonin for Tumoral Calcinosis
OBJECTIVES: I. Determine whether intermittent, long-term, subcutaneous administration of calcitonin increases phosphaturia, reduces hyperphosphatemia, and increases intact parathyroid hormone levels in patients with tumoral calcinosis.
II. Determine whether calcitonin reduces or prevents tumor recurrence. III. Determine whether hyperphosphatemia abolishes the normal circadian pattern of serum phosphorus.
IV. Determine how repetitive calcitonin administration alters the biochemical markers of bone metabolism in osteopenic patients with tumoral calcinosis.
|Study Design:||Primary Purpose: Treatment|
|Study Start Date:||November 1992|
PROTOCOL OUTLINE: Patients are treated with subcutaneous injections of salmon calcitonin every 3 weeks. Ondansetron premedication and intravenous hydration are also administered.
Patients are followed for disease progression and tumor recurrence.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004358
|United States, Illinois|
|Children's Memorial Hospital, Chicago|
|Chicago, Illinois, United States, 60614|
|Study Chair:||Craig B. Langman||Ann & Robert H Lurie Children's Hospital of Chicago|